- Home
- WST vs DXCM Comparison
WST vs DXCM Comparison
Compare WST & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WST | DXCM |
|---|---|---|
| Founded | 1923 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 25.9B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | WST | DXCM |
|---|---|---|
| Price | $266.98 | $66.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $346.78 | $87.90 |
| AVG Volume (30 Days) | 661.3K | ★ 5.3M |
| Earning Date | 10-23-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | 0.17 | ★ 7.75 |
| EPS | ★ 6.75 | 1.80 |
| Revenue | $3,017,900,000.00 | ★ $4,515,900,000.00 |
| Revenue This Year | $7.01 | $17.41 |
| Revenue Next Year | $6.20 | $12.78 |
| P/E Ratio | $39.63 | ★ $37.27 |
| Revenue Growth | 4.92 | ★ 14.21 |
| 52 Week Low | $187.43 | $54.11 |
| 52 Week High | $348.90 | $93.25 |
Technical Indicators
Market Signals| Indicator | WST | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 60.62 |
| Support Level | $263.38 | $64.00 |
| Resistance Level | $274.56 | $69.77 |
| Average True Range (ATR) | 7.32 | 1.96 |
| MACD | -0.79 | 0.78 |
| Stochastic Oscillator | 15.52 | 72.06 |
Price Performance
Historical ComparisonAbout WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.